Dorottya Muhl
Overview
Explore the profile of Dorottya Muhl including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
9
Citations
22
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Kokas B, Krizsany G, Pekli D, Meltzer A, Bardos D, Rozsa B, et al.
Orv Hetil
. 2024 Sep;
165(36):1433-1439.
PMID: 39244743
No abstract available.
2.
Szentmartoni G, Muhl D, Csanda R, Szasz A, Herold Z, Dank M
Biomedicines
. 2024 Mar;
12(3).
PMID: 38540206
Ten percent of patients with breast cancer, and probably somewhat more in patients with ovarian cancer, have inherited germline DNA mutations in the breast and ovarian cancer genes and ....
3.
Barna A, Herold Z, Acs M, Bazsa S, Gajdacsi J, Garay T, et al.
Int J Mol Sci
. 2023 Sep;
24(18).
PMID: 37761986
Cancer-related immunity plays a significant role in the outcome of ovarian cancer, but the exact mechanisms are not fully explored. A retrospective, real-life observational study was conducted including 57 advanced...
4.
Dank M, Muhl D, Polhos A, Csanda R, Herold M, Kovacs A, et al.
Genes (Basel)
. 2023 Sep;
14(9).
PMID: 37761848
Background: Breast cancer has been categorized into molecular subtypes using immunohistochemical staining (IHC) and fluorescence in situ hybridization (FISH) since the early 2000s. However, recent research suggests that gene expression...
5.
Dank M, Muhl D, Herold M, Hornyak L, Szasz A, Herold Z
J Clin Med
. 2022 Aug;
11(16).
PMID: 36013050
Background: Programmed death-ligand 1 (PD-L1) and programmed cell death protein 1 (PD-1) have been reported as possibly favorable prognostic factors in colorectal cancer (CRC). However, their longitudinal effect is unknown....
6.
Agoston E, Acs B, Herold Z, Fekete K, Kulka J, Nagy A, et al.
Genes (Basel)
. 2022 Apr;
13(4).
PMID: 35456394
Cancer-related immunity has been identified as playing a key role in the outcome of colorectal cancer (CRC); however, the exact mechanisms are only partially understood. In this study, we evaluated...
7.
Muhl D, Herold M, Herold Z, Hornyak L, Szasz A, Dank M
Cancers (Basel)
. 2022 Feb;
14(3).
PMID: 35158926
Background: 1α,25-dihydroxycholecalciferol (1,25(OH)D) and homocysteine are known to play a role in the pathophysiology of colorectal cancer (CRC). In health, the two changes are inversely proportional to each other, but...
8.
Petenyi F, Garay T, Muhl D, Izso B, Karaszi A, Borbenyi E, et al.
Diseases
. 2021 Nov;
9(4).
PMID: 34842668
Methods: A retrospective single-center case-control study was conducted with the inclusion of 78 inoperable PDAC patients. Age-, sex-, chemotherapy-, stage-, and ascites formation-matched patients were assigned to two equal groups...
9.
Tokes T, Tokes A, Szentmartoni G, Kiszner G, Muhl D, Molnar B, et al.
Pathol Oncol Res
. 2019 Aug;
26(3):1499-1510.
PMID: 31446607
We aimed to analyze the expression of cell-cycle regulation markers - minichromosome maintenance protein 2 (MCM2), Ki-67, Cyclin-A and phosphohistone-H3 (PHH3) - in pre-treatment core-biopsy samples of breast carcinomas in...